Literature DB >> 17890466

Exhaled nitric oxide daily evaluation is effective in monitoring exposure to relevant allergens in asthmatic children.

Alessandro Bodini1, Diego Peroni, Attilio Loiacono, Silvia Costella, Roberta Pigozzi, Eugenio Baraldi, Attilio L Boner, Giorgio L Piacentini.   

Abstract

BACKGROUND: Though asthma is an airway inflammatory disease, the assessment of treatment efficacy is mainly based on symptom monitoring and the evaluation of lung function parameters. This study was aimed to evaluate the feasibility of exhaled nitric oxide monitoring in allergic asthmatic children who were exposed to relevant allergens in their homes.
METHODS: Twenty-two children allergic to mites underwent twice-daily fractional exhaled nitric oxide (FeNO) therapy using a portable device (NIOX MINO; Aerocrine AB; Stockholm, Sweden) and peak expiratory flow (PEF) measurements before, during, and after periods of natural exposure to mite allergens. The children were admitted to the study if they had lived in a mite-free environment for 3 months. They were observed in this environment for 10 days and then were moved to a site with natural mite exposure at sea level for 19 days. Finally, they were relocated to the mite-free environment for a period of 6 days for follow-up measurements.
RESULTS: Significant differences were seen between the mite-free baseline FeNO level (26.4 parts per billion [ppb]; range, 19.3 to 36.2 ppb) and FeNO levels measured during natural mite exposure (37.3 ppb; 27.3 to 51 ppb) and after natural mite exposure (34.9 natural mite exposure; 25.2 to 48.2 ppb). Six children reported asthma symptoms during the mite exposure, and an increase in FeNO was observed in each case (p<0.031); PEF values showed no significant differences, whether between the different environments or between different periods.
CONCLUSIONS: These data give further evidence for a possible role of frequent determinations of FeNO in order to promptly assess changes in the level of airway inflammation in asthmatic children.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17890466     DOI: 10.1378/chest.07-1025

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.

Authors:  Raed A Dweik; Peter B Boggs; Serpil C Erzurum; Charles G Irvin; Margaret W Leigh; Jon O Lundberg; Anna-Carin Olin; Alan L Plummer; D Robin Taylor
Journal:  Am J Respir Crit Care Med       Date:  2011-09-01       Impact factor: 21.405

2.  Allergen exposure modifies the relation of sensitization to fraction of exhaled nitric oxide levels in children at risk for allergy and asthma.

Authors:  Joanne E Sordillo; Tara Webb; Doris Kwan; Jimmy Kamel; Elaine Hoffman; Donald K Milton; Diane R Gold
Journal:  J Allergy Clin Immunol       Date:  2011-04-03       Impact factor: 10.793

3.  Environmental effects on fractional exhaled nitric oxide in allergic children.

Authors:  Stefania La Grutta; Giuliana Ferrante; Velia Malizia; Fabio Cibella; Giovanni Viegi
Journal:  J Allergy (Cairo)       Date:  2011-11-17

4.  Seasonal changes in nasal cytology in mite-allergic patients.

Authors:  Matteo Gelardi; Diego G Peroni; Cristoforo Incorvaia; Nicola Quaranta; Concetta De Luca; Salvatore Barberi; Ilaria Dell'albani; Massimo Landi; Franco Frati; Olivier de Beaumont
Journal:  J Inflamm Res       Date:  2014-03-28

5.  Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC).

Authors:  Enrico Heffler; Giovanna Elisiana Carpagnano; Elisabetta Favero; Giuseppe Guida; Mauro Maniscalco; Andrea Motta; Giovanni Paoletti; Giovanni Rolla; Eugenio Baraldi; Vincenza Pezzella; Giorgio Piacentini; Stefano Nardini
Journal:  Multidiscip Respir Med       Date:  2020-02-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.